Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: A systematic review of the published literature with subgroup analysis

Browman, George P.; Hodson, D. Ian; Bestic, Nancy; Zuraw, Lisa

doi:10.1002/hed.1081

Cited by 248 publications

(154 citation statements)

References 47 publications

Supporting

Mentioning

153

Contrasting

Unclassified

Order By: Relevance

“…26,27 Hence, we next sought to investigate the regulation of chemokine receptors on tumor cells, during the exposure to this antineoplastic agent. CXCR4-expressing ACC cells were exposed to sublethal doses of cisplatin at the concentrations of 1, 3 and 9 lg/ml.…”

Section: The Antineoplastic Agent Cisplatin Upregulates Cxcr4 On Tumomentioning

confidence: 99%

Chemokine receptors in head and neck cancer: Association with metastatic spread and regulation during chemotherapy

Müller

Sonkoly

Eulert

et al. 2005

Intl Journal of Cancer

View full text Add to dashboard Cite

Head and neck carcinomas are histologically and clinically heterogeneous. While squamous cell carcinomas (SCC) are characterized by lymphogenous spread, adenoid cystic carcinomas (ACC) disseminate preferentially hematogenously. To study cellular and molecular mechanisms of organ-specific metastasis, we used SCC and ACC cell lines and tumor tissues, obtained from patients with primary or metastatic disease. Comprehensive analysis at the mRNA and protein level of human chemokine receptors showed that SCC and ACC cells exhibited distinct and nonrandom expression profiles for these receptors. SCC predominantly expressed receptors for chemokines homeostatically expressed in lymph nodes, including CC chemokine receptor (CCR) 7 and CXC chemokine receptor (CXCR)5. No difference in expression of chemokine receptors was seen in primary SCC and corresponding lymph node metastases. In contrast to SCC, ACC cells primarily expressed CXCR4. In chemotaxis assays, ACC cells were responsive to CXCL12, the ligand for CXCR4. Exposure of ACC cells to cisplatin resulted in upregulation of CXCR4 on the cell surface, which was repressed by the transcriptional inhibitor, a-amanitin. Treatment of ACC cells with CXCL12 resulted in the activation of Akt and ERK1/2 pathways. Furthermore, CXCL12 suppressed the rate of apoptosis induced by cisplatin in ACC cells, suggesting that signaling via CXCR4 may be part of a tumor cell survival program. Discrimination of the chemokine receptor profile in SCC and ACC in vitro and in tissues provided insights into their distinct biologic and clinical characteristics as well as indications that chemokine receptors might serve as future therapeutic targets in these malignancies. ' 2005 Wiley-Liss, Inc.Key words: head and neck cancer; squamous cell carcinoma; adenoid cystic carcinoma; chemokine receptor; metastasis Head and neck carcinomas (HNC) include tumors with different histological phenotypes and distinct clinical characteristics. Squamous cell carcinomas (SCC) of the upper aerodigestive tract mucosa represent the most common histological subtype.

show abstract

Section: The Antineoplastic Agent Cisplatin Upregulates Cxcr4 On Tumomentioning

confidence: 99%

Chemokine receptors in head and neck cancer: Association with metastatic spread and regulation during chemotherapy

Müller

Sonkoly

Eulert

et al. 2005

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…Recently, Browman et al 17 reported a metaanalysis including 18 trials with 3,192 patients, in which concurrent chemotherapy-radiation therapy was compared to radiation therapy alone (Table 3). Overall, the chemotherapy-radiation therapy arm was again superior to radiation therapy alone (P<.00001).…”

Section: Locally Advanced Resectable Cancermentioning

confidence: 99%

Treatment of Locally Advanced Head and Neck Cancer: Historical and Critical Review

Al‐Sarraf

2002

Cancer Control

105

View full text Add to dashboard Cite

Background Advanced squamous cell cancers of the head and neck have traditionally been associated with high rates of morbidity and mortality. Advances in management have improved outcomes for most of these patients. Methods The author reviews the historical progress in management of these difficult tumors and adds his own wide experience to describe and evaluate newer approaches to management. Results Over the last 10 years, overall survival rates for patients with head and neck cancers have improved as has quality of life. New standards of care have been defined for patients with nasopharyngeal cancer and for those with advanced unresectable disease. Organ preservation is more commonly achieved. Conclusions Newer targeted therapies are likely to add to the progress that has already been achieved in the multimodality management of patients with head and neck cancers.

show abstract

“…Patients with unresectable disease usually undergo CCRT; the 3-year OS rates of CCRT with cisplatin-based chemotherapy were reported to be 20-30% (1-3). Although CCRT is superior to radiotherapy alone in improving survival, increasing toxicity must be considered (20,21). To improve treatment outcomes, CCRT with S-1 was administered to patients with advanced oral SCC.…”

Section: Discussionmentioning

confidence: 99%

Concurrent chemoradiotherapy with S-1 in patients with stage III–IV oral squamous cell carcinoma: A retrospective analysis of nodal classification based on the neck node level

Murakami

Semba

Kawahara

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. The aim of the present study was to retrospectively evaluate the treatment outcomes of concurrent chemoradiotherapy (CCRT) with S-1, an oral fluoropyrimidine anticancer agent, for advanced oral squamous cell carcinoma (SCC). The study population consisted of 47 patients with clinical stage III or IV oral SCC, who underwent CCRT with S-1. Pretreatment variables, including patient age, clinical stage, T classification, midline involvement of the primary tumor and nodal status, were analyzed as predictors of survival. In addition to the N classification (node-positive, multiple and contralateral), the prognostic impact of the level of nodal involvement was assessed. Nodal involvement was mainly observed at levels Ib and II; involvement at levels Ia and III-V was considered to be anterior and inferior extension, respectively, and was recorded as extensive nodal involvement (ENI). The 3-year overall survival (OS) and progression-free survival (PFS) rates were 37 and 27%, respectively. A finding of ENI was a significant factor for OS [hazard ratio (HR)=2.16; 95% confidence interval (CI): 1.03-4.55; P=0.038] and PFS (HR=2.65; 95% CI: 1.32-5.33; P=0.005); the 3-year OS and PFS rates in patients with vs. those without ENI were 23 vs. 50% and 9 vs. 43%, respectively. The other variables were not significant. Therefore, CCRT with S-1 may be an alternative treatment for advanced oral SCC; favorable outcomes are expected in patients without ENI.

show abstract

Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: A systematic review of the published literature with subgroup analysis

Abstract: Platinum-based concomitant CT and RT is superior to conventional RT alone in improving survival in locally advanced SCHNC. Subgroup analyses can be used to help in choosing the most appropriate concomitant regimen.

Cited by 248 publications

References 47 publications

Chemokine receptors in head and neck cancer: Association with metastatic spread and regulation during chemotherapy

Chemokine receptors in head and neck cancer: Association with metastatic spread and regulation during chemotherapy

Treatment of Locally Advanced Head and Neck Cancer: Historical and Critical Review

Concurrent chemoradiotherapy with S-1 in patients with stage III–IV oral squamous cell carcinoma: A retrospective analysis of nodal classification based on the neck node level

Contact Info

Product

Resources

About